Lancet Respirat Med:阿司匹林对健康老年人败血症相关死亡的影响

2020-09-18 MedSci原创 MedSci原创

败血症是一个严重的全球性健康问题,是导致死亡和残疾的主要原因。提供一种简单的、基于社区的预防策略可以大大减少败血症的负担。本研究(ANTISEPSIS)旨在确定低剂量阿司匹林是否可以减少老年人败血症相

败血症是一个严重的全球性健康问题,是导致死亡和残疾的主要原因。提供一种简单的、基于社区的预防策略可以大大减少败血症的负担。本研究(ANTISEPSIS)旨在确定低剂量阿司匹林是否可以减少老年人败血症相关的死亡或住院治疗。

ANTISEPSIS是ASPREE研究(老年人服用低剂量阿司匹林[100 mg/天]的预防作用)的一个子研究,纳入了澳大利亚队列的受试者,纳入标准是70岁及以上的没有重大疾病的老年人。将受试者随机(1:1)分组,并按一般实践和年龄进行分层。主要终点是败血症相关的死亡。

2010年3月10日-2014年12月24日,共评估了20288位个体,其中16703位符合要求被纳入研究,中位随访了4.6年(范围 3.6-5.6年)。8322位患者(49.8%)接受阿司匹林预防,8381位患者服用安慰剂。有203例死亡被认定与败血症相关。多变量分析显示,阿司匹林组和安慰剂组的败血症相关死亡率相似(阿司匹林 vs 安慰剂,HR 1.08,95% CI 0.82-1.43,p=0.57)。不良反应与ASPREE研究报道的一致。

综上所述,低剂量阿司匹林治疗不能减少社区居民老年人败血症相关性死亡。本研究结果不支持采用阿司匹林作为减轻该人群败血症复旦的基础预测策略。

原始出处:

Damon P Eisen, et al. Effect of aspirin on deaths associated with sepsis in healthy older people (ANTISEPSIS): a randomised, double-blind, placebo-controlled primary prevention trial. The Lancet Respiratory Medicine. September 17, 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1830828, encodeId=b99b1830828a3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 28 10:28:15 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610707, encodeId=1ba91610e079b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 20 02:28:15 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886474, encodeId=3c8f8864e48c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd3a2173825, createdName=1205a032m39(暂无昵称), createdTime=Fri Sep 18 21:36:43 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033973, encodeId=7e3c10339e399, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Fri Sep 18 14:28:15 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886374, encodeId=19a68863e440, content=低剂量<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>治疗不能减少社区居民老年人<a href='/topic/show?id=a63592333b0' target=_blank style='color:#2F92EE;'>#败血症#</a>相关性死亡, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林), TopicDto(id=92333, encryptionId=a63592333b0, topicName=败血症)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Sep 18 13:09:25 CST 2020, time=2020-09-18, status=1, ipAttribution=)]
    2020-10-28 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1830828, encodeId=b99b1830828a3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 28 10:28:15 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610707, encodeId=1ba91610e079b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 20 02:28:15 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886474, encodeId=3c8f8864e48c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd3a2173825, createdName=1205a032m39(暂无昵称), createdTime=Fri Sep 18 21:36:43 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033973, encodeId=7e3c10339e399, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Fri Sep 18 14:28:15 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886374, encodeId=19a68863e440, content=低剂量<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>治疗不能减少社区居民老年人<a href='/topic/show?id=a63592333b0' target=_blank style='color:#2F92EE;'>#败血症#</a>相关性死亡, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林), TopicDto(id=92333, encryptionId=a63592333b0, topicName=败血症)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Sep 18 13:09:25 CST 2020, time=2020-09-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1830828, encodeId=b99b1830828a3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 28 10:28:15 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610707, encodeId=1ba91610e079b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 20 02:28:15 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886474, encodeId=3c8f8864e48c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd3a2173825, createdName=1205a032m39(暂无昵称), createdTime=Fri Sep 18 21:36:43 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033973, encodeId=7e3c10339e399, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Fri Sep 18 14:28:15 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886374, encodeId=19a68863e440, content=低剂量<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>治疗不能减少社区居民老年人<a href='/topic/show?id=a63592333b0' target=_blank style='color:#2F92EE;'>#败血症#</a>相关性死亡, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林), TopicDto(id=92333, encryptionId=a63592333b0, topicName=败血症)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Sep 18 13:09:25 CST 2020, time=2020-09-18, status=1, ipAttribution=)]
    2020-09-18 1205a032m39(暂无昵称)

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1830828, encodeId=b99b1830828a3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 28 10:28:15 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610707, encodeId=1ba91610e079b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 20 02:28:15 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886474, encodeId=3c8f8864e48c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd3a2173825, createdName=1205a032m39(暂无昵称), createdTime=Fri Sep 18 21:36:43 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033973, encodeId=7e3c10339e399, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Fri Sep 18 14:28:15 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886374, encodeId=19a68863e440, content=低剂量<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>治疗不能减少社区居民老年人<a href='/topic/show?id=a63592333b0' target=_blank style='color:#2F92EE;'>#败血症#</a>相关性死亡, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林), TopicDto(id=92333, encryptionId=a63592333b0, topicName=败血症)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Sep 18 13:09:25 CST 2020, time=2020-09-18, status=1, ipAttribution=)]
    2020-09-18 goodbing

    顶刊就是不一样,质量很高,内容精彩!学到很多

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1830828, encodeId=b99b1830828a3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 28 10:28:15 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610707, encodeId=1ba91610e079b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 20 02:28:15 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886474, encodeId=3c8f8864e48c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd3a2173825, createdName=1205a032m39(暂无昵称), createdTime=Fri Sep 18 21:36:43 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033973, encodeId=7e3c10339e399, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Fri Sep 18 14:28:15 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886374, encodeId=19a68863e440, content=低剂量<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>治疗不能减少社区居民老年人<a href='/topic/show?id=a63592333b0' target=_blank style='color:#2F92EE;'>#败血症#</a>相关性死亡, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林), TopicDto(id=92333, encryptionId=a63592333b0, topicName=败血症)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Sep 18 13:09:25 CST 2020, time=2020-09-18, status=1, ipAttribution=)]
    2020-09-18 lovetcm

    低剂量#阿司匹林#治疗不能减少社区居民老年人#败血症#相关性死亡

    0

相关资讯

NEJM:替格瑞洛联合阿司匹林用于轻中度卒中患者二次卒中的预防

研究认为,在轻中度急性非心源性缺血性中风或未接受静脉或血管内溶栓治疗的短暂性脑缺血发作患者中,替卡格雷联合阿司匹林治疗可降低患者30天内中风或死亡风险

GUT:阿司匹林会大大增加老年人胃肠道出血的风险

阿司匹林是心内科医生最常用的一种药物,因为阿司匹林是心血管疾病最基础的用药,是基石!那自然我们遇到的阿司匹林导致的副作用也是最常见。

Nat Commun:阿司匹林的替代药?科学家研制出不会增加出血风险的合成血液抗凝剂!

患有肺栓塞、缺血性中风和心肌梗塞等由于血栓形成而导致疾病的患者,通常会服用阿司匹林和氯吡格雷等“血液稀释剂”药物,以阻止血凝块形成或增大,帮助血液顺畅流动,防止疾病进一步的发展。

Brilinta联合阿司匹林:III期研究证实继发性中风死亡率降低17%

“大约四分之一的中风幸存者会经历第二次中风,并且在初次事件后第一个月内发生风险特别高。早期治疗对预防可能致残或致命的中风很重要。”

JNCI:惊!“神药”阿司匹林会加速老年人晚期癌症的进展,增加死亡风险

阿司匹林被称为“神药”,它除了能够镇痛抗炎之外,还在预防心血管疾病和各种癌症中发挥重要作用。100多年来,阿司匹林的疗效是有目共睹的,然而,近日发表在《国家癌症研究所杂志》上的一项研究对此提出了质疑。

Circulation:峰回路转!有效降低双重抗血小板疗法出血风险的新策略

阿司匹林和P2Y12抑制剂的双重抗血小板疗法已被证实可降低PCI或急性冠脉综合征后的MACE风险,但同时会增加出血风险。本研究旨在评估停用阿司匹林而采用P2Y12抑制剂单一疗法的安全性。